Skip to main content

Table 1 Baseline characteristics of patients according to treatment arm

From: The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals

  HIV-negative HIV-positive
  Arm A No HAART
Arm B
NRTI-containing
Arm C1
NRTI-free
Arm C2
  n = 50 n = 49 n = 49 n = 20
Age [years]** 41 (25 - 55) 39 (24 - 47) 42 (30 - 47) 43 (34 - 61)
Male sex* [%] 60 74 76 85
Transmission risk [%]     
    IVDU 40 33 25 5
    Blood products 10 2 8 -
    Sexual 8 2 10 10
    other 8 2 - -
    unknown/missing 34 61 57 85
HCV-genotype [%]
    1 52 51 51 50
    2 6 8 4 5
    3 38 27 31 40
    4 - 8 10 5
    other 4 4 2 -
    untypable - 2 2 -
HCV-RNA [IU/ml, log 10 ] 5.7 (4.5 - 6.8) 5.7 (4.1 - 6.7) 5.5 (4.4 - 6.8) 5.9 (4.3 - 7.3)
≥ 500 000 IU/ml [%] 56 57 41 65
    ALT [IU/l] 61 (21 - 179) 68 (17 - 212) 71 (30 - 221) 75 (26 - 231)
HAART [%]
    PI/NNRTI/3 × NUC - - 57/29/12 95/5/0
    AZT    33 -
    d4T    18 -
    ABC    31 -
    3TC/FTC    98 -
    TDF    47 -
HIV-RNA [copies/ml, log 10 ]** - 3.9 (1.9 - 4.9) 1.7 (1.7 - 3.5) 1.7 (1.7 - 4.5)
CD4-cellcount
    [/μl]** - 580 (301 - 1042) 491 (222 - 781) 390 (152 - 846)
    [%] - 27 (15 - 41) 27 (13 - 40) 22 (16 - 41)
  1. * Statistically significant difference comparing arm A with arms B and C (HIV-positive vs. HIV-negative)
  2. ** Statistically significant difference comparing arm B versus C1 versus C2
  3. Data shown as percent of patients or median (95% range). NRTI nucleos(t)ide reverse transcriptase inhibitor, IVDU intravenous drug abuse, other double infections, e.g. genotype 1 and 2 infection; PI protease inhibitor containing HAART, NNRTI non-nucleoside reverse transcriptase inhibitor containing HAART, 3xNUC HAART based on at least 3 nucleos(t)ides, AZT zidovudine, d4T stavudine, ABC abacavir, TDF tenofovir DF